TOKYO (Reuters) – Japan’s Shionogi & Co Ltd said on Wednesday it started a Phase II/III clinical trial for its COVID-19 vaccine candidate.
The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The company will also prepare to conduct multiple trials globally, it said.
(Reporting by Rocky Swift; Editing by Jacqueline Wong)
